Literature DB >> 21266852

Early epigenetic events regulate the adaptive immune response gene CIITA.

Ninad T Mehta1, Agnieszka D Truax, Nathaniel H Boyd, Susanna F Greer.   

Abstract

Precise regulation of Major Histocompatibility class II (MHC II) genes plays important roles in initiation, propagation and termination of adaptive immune responses by controlling antigen presentation to CD4+ T cells. MHC II genes are constitutively expressed in only a few cell types and are inducibly expressed by the inflammatory response cytokine interferon gamma (IFNγ) in all nucleated cells. The regulation of MHC II is tightly controlled by a Master Regulator, the class II transactivator (CIITA), which is a general regulator of both constitutive and inducible MHC II expression. Although much is known about the transcription factors necessary for CIITA expression, less is known about the epigenetic modifications and the requisite enzymes needed to provide these transcription factors access to DNA. We show here that multiple epigenetic changes occur at the IFNγ inducible CIITA promoter within 20' of IFNγ stimulation and that these changes correlate with the opening of the promoter and the initiation of transcription. Our study links these rapidly occurring epigenetic events at the inducible CIITA promoter to decreased promoter binding of the histone methyltransferase EZH2, and shows that decreased promoter binding of EZH2 transforms this previously tightly regulated and cytokine inducible promoter into a constitutively active and dysregulated gene.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21266852     DOI: 10.4161/epi.6.4.14516

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  13 in total

1.  CIITA: a master regulator of adaptive immunity shows its innate side in the bone.

Authors:  Mary C Nakamura
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

2.  Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.

Authors:  Chulbul M Ahmed; Ezra N Noon-Song; Kaisa Kemppainen; Massimo P Pascalli; Howard M Johnson
Journal:  J Neuroimmunol       Date:  2012-10-27       Impact factor: 3.478

3.  ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells.

Authors:  Hye Suk Yoon; Christopher D Scharer; Parimal Majumder; Carl W Davis; Royce Butler; Wendy Zinzow-Kramer; Ioanna Skountzou; Dimitrios G Koutsonanos; Rafi Ahmed; Jeremy M Boss
Journal:  J Immunol       Date:  2012-07-30       Impact factor: 5.422

Review 4.  Major histocompatibility complex genomics and human disease.

Authors:  John Trowsdale; Julian C Knight
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-07-15       Impact factor: 8.929

5.  Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways.

Authors:  Mohamed Abou El Hassan; Katherine Huang; Manoja B K Eswara; Michael Zhao; Lan Song; Tao Yu; Yu Liu; Jeffrey C Liu; Sean McCurdy; Anqi Ma; Joan Wither; Jian Jin; Eldad Zacksenhaus; Jeffrey L Wrana; Rod Bremner
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

6.  Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.

Authors:  Paula I Gonzalez-Ericsson; Julia D Wulfkhule; Rosa I Gallagher; Xiaopeng Sun; Margaret L Axelrod; Quanhu Sheng; Na Luo; Henry Gomez; Violeta Sanchez; Melinda Sanders; Lajos Pusztai; Emanuel Petricoin; Kim R M Blenman; Justin M Balko
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

7.  Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.

Authors:  Agnieszka D Truax; Meghna Thakkar; Susanna F Greer
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

8.  Expression regulation of major histocompatibility complex class I and class II encoding genes.

Authors:  Peter J van den Elsen
Journal:  Front Immunol       Date:  2011-10-04       Impact factor: 7.561

9.  IFN signaling: how a non-canonical model led to the development of IFN mimetics.

Authors:  Howard M Johnson; Ezra Neptune Noon-Song; Rea Dabelic; Chulbul M Ahmed
Journal:  Front Immunol       Date:  2013-07-25       Impact factor: 7.561

10.  Analysis of epigenetic changes in survivors of preterm birth reveals the effect of gestational age and evidence for a long term legacy.

Authors:  Mark N Cruickshank; Alicia Oshlack; Christiane Theda; Peter G Davis; David Martino; Penelope Sheehan; Yun Dai; Richard Saffery; Lex W Doyle; Jeffrey M Craig
Journal:  Genome Med       Date:  2013-10-18       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.